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Background: The BioFreedom stent is a novel drug-eluting stent that releases Biolimus A9 directly from a mechanically modified textured surface 
without polymer thereby eliminating polymer-associated tissue responses. The aim of this study was to evaluate the short- and mid-term efficacy of 
the BioFreedom vs. TAXUS Liberté stents with durable polymer (PES).
Methods: BioFreedom-FIM was a multicenter randomized trial comparing BioFreedom vs. PES in de novo native coronary artery lesions. Volumetric 
IVUS was performed at 4 months in 75 patients treated with standard-dose BioFreedom (SD: n=25), low-dose (LD: n=26), or PES (n=24), and at 12 
months in 104 patients treated with SD (n=32), LD (n=36), or PES (n=36).
Results: At 4 months, % neointimal volume (NIV) and maximum cross sectional narrowing (max CSN) were significantly reduced in SD compared 
to both LD and PES. % NIV and max CSN in SD and LD increased significantly from 4 to 12 months whereas no significant increase was seen in PES. 
At 12 months, % NIV and max CSN were similar among 3 groups. At 12 months, SD and PES showed no difference in vessel change while LD showed 
mild positive vessel remodeling. There was no late acquired incomplete stent apposition at either 4 or 12 months in any stent group.
Conclusion: In this first human experience, the novel polymer-free BioFreedom stents demonstrated comparable efficacy in neointimal inhibition 
to durable-polymer PES up to 12 months, while embracing potential advantage of shorter need of dual antiplatelet therapy. 
